Novak Djokovic alcanzó las semifinales de Wimbledon por 14toa ocasión, un récord en la categoría masculina, y sigue en la ...

Goal 2 is about creating a world free of hunger by 2030.The global issue of hunger and food insecurity has shown an alarming increase since 2015, a trend exacerbated by a combination of factors ...

CERo Therapeutics Holdings Inc (NASDAQ:CERO) shares are trading higher Tuesday after the company received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for CER-1236.

The ODD designation qualifies CERo and CER-1236 for certain incentives, which include FDA assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, exemption from the ...

Wherever Penta travels, the catchphrase "Cero Miedo" is right alongside him, generally accompanied by Penta's equally famous hand gesture, one that has been adopted by Penta's biggest fan, NFL ...

SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) announced Wednesday that its board of directors has approved a one-for-twenty reverse stock split of the company’s common ...

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia (AML), announcing today the successful dosing of the first patient in its ...

CERO Therapeutics announces first patient dosed in Phase 1 trial of CER-1236 for acute myeloid leukemia, with upcoming ASCO presentation.

CERO Company Profile CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.